Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned?
{{output}}
Background/objective: Crohn's disease is associated with a high economic burden for the Spanish National Healthcare System, driven by pharmacological expenses. Following the recent incorporation of ustekinumab biosimilars into t... ...
